Authors’ response

We read with interest these 2 separate correspondences, both authored by employees of Aimmune Therapeutics.1,2 We certainly appreciate their interest in our qualitative research study about motivations for seeking peanut allergy therapy.3 With the potential approval of 2 drugs to help treat peanut allergy in the next year, this is a timely topic. Both queries highlight alleged problems regarding our methods and conclusion and voice rather fervent, somewhat misplaced, comments and inappropriate posturing regarding Aimmune's interpretation of DBV's topline data for their phase 3 trial.

https://ift.tt/2JprmvU